Addressing Challenges in Antibody-Drug Conjugate Development

Guest Speaker

Dr. Hengshuo Liu

Technical Sales Supervisor

Topic:

Addressing Challenges in Antibody-Drug Conjugate Development

Introduction

Antibody-drug conjugates (ADCs) are a cutting-edge class of targeted cancer therapies that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, allowing for the precise delivery of chemotherapy to cancer cells while minimizing damage to healthy tissue. Despite their promise, the development of ADCs faces significant challenges, including optimizing the stability of the conjugate, ensuring effective drug release at the target site, and managing potential off-target effects. This webinar will explore the latest advancements in ADC technology and strategies to overcome these critical hurdles in drug development.

Organisers